• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Editas Medicine Announces Second Quarter 2024 Results and Business Updates

    8/7/24 7:00:00 AM ET
    $EDIT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $EDIT alert in real time by email

    On track to present additional clinical data from the RUBY trial and the EdiTHAL trial by year-end

    In vivo preclinical proof-of-concept for an undisclosed indication on-track by year-end

    Strong financial position with runway into 2026

    CAMBRIDGE, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a clinical-stage gene editing company, today reported financial results for the second quarter 2024 and provided business updates.

    "We made significant progress in all three pillars of our strategy this quarter, particularly reni-cel as we shared a substantial clinical update mid-year and continued to enroll and dose at an accelerated pace. With these data, we are highly confident reni-cel is well positioned to be a differentiated, best-in-class product for the treatment of sickle cell disease," commented Gilmore O'Neill, M.B., M.M.Sc., President and Chief Executive Officer, Editas Medicine. "I am proud of the Editas team's work and our advancement in the first half of 2024 as we move closer to becoming a commercial-stage company and continue developing clinically differentiated, transformational medicines for people living with serious, previously untreatable diseases."

    Recent Achievements and Outlook

    Ex Vivo Hemoglobinopathies

    • Reni-cel (renizgamglogene autogedtemcel, previously EDIT-301) for Severe Sickle Cell Disease (SCD)
      • On-track to present a substantive clinical data set of sickle cell patients with considerable clinical follow-up in the RUBY trial by year-end 2024.
      • Completed enrollment of the adolescent cohort of the Phase 1/2/3 RUBY trial for SCD.
      • Manufacturing drug product for the initial adolescent cohort patients.
      • The Company continues to dose adult patients in the RUBY trial. As previously disclosed, the Company has completed enrollment of the adult cohort.
    • Reni-cel for Transfusion-dependent Beta Thalassemia (TDT)

      • On-track to present additional clinical data from the EdiTHAL trial by year-end 2024.
      • The Company completed enrollment of the adult cohort of the EdiTHAL trial for TDT and continues to dose patients.

    In Vivo Medicines

    • On-track to establish in vivo preclinical proof-of-concept for an undisclosed indication by year-end.
    • The Company continues to pursue an in vivo strategy and approach aimed at driving functional upregulation of gene expression to address loss of function or deleterious mutations.

    Second Quarter 2024 Financial Results

    Cash, cash equivalents, and marketable securities as of June 30, 2024, were $318.3 million compared to $376.8 million as of March 31, 2024. The Company expects the existing cash, cash equivalents, and marketable securities together with the near-term annual license fees and the contingent upfront payment payable under its license agreement with Vertex Pharmaceuticals, Incorporated, to fund operating expenses and capital expenditures into 2026.

    Second Quarter 2024

    • For the three months ended June 30, 2024, net loss attributable to common stockholders was $67.6 million, or $0.82 per share, compared to net loss of $40.3 million, or $0.56 per share, for the same period in 2023.
    • Collaboration and other research and development revenues decreased to $0.5 million for the three months ended June 30, 2024, compared to $2.9 million for the same period in 2023. The decrease is primarily attributable to reduced drug supply activity with collaborators.
    • Research and development expenses increased by $24.4 million to $54.2 million for the three months ended June 30, 2024, compared to $29.8 million for the same period in 2023. The increase is primarily related to clinical and manufacturing costs related to the accelerated progression of the Company's reni-cel program as well as costs attributable to in vivo research and discovery.
    • General and administrative expenses increased by $1.0 million to $18.2 million for the three months ended June 30, 2024, compared to $17.2 million for the same period in 2023. The increase is primarily attributable to increased intellectual property and patent related fees due to increased legal activity.

    Conference Call

    The Editas Medicine management team will host a conference call and webcast today at 8:00 a.m. ET to provide and discuss a corporate update and financial results for the second quarter of 2024. To access the call, please dial 1-800-343-4849 (domestic) or 1-203-518-9848 (international) and ask for the Editas Medicine earnings call. A live webcast of the call will also be available on the Investors section of the Editas Medicine website at www.editasmedicine.com, and a replay will be available approximately two hours after its completion.

    About Editas Medicine

    As a clinical-stage gene editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas12a and CRISPR/Cas9 genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. Editas Medicine is the exclusive licensee of Broad Institute's Cas12a patent estate and Broad Institute and Harvard University's Cas9 patent estates for human medicines. For the latest information and scientific presentations, please visit www.editasmedicine.com.

    Forward-Looking Statements

    This press release contains forward-looking statements and information within the meaning of The Private Securities Litigation Reform Act of 1995. The words ‘‘anticipate,'' ‘‘believe,'' ‘‘continue,'' ‘‘could,'' ‘‘estimate,'' ‘‘expect,'' ‘‘intend,'' ‘‘may,'' ‘‘plan,'' ‘‘potential,'' ‘‘predict,'' ‘‘project,'' ‘‘target,'' ‘‘should,'' ‘‘would,'' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include statements regarding the initiation, timing, progress and results of the Company's preclinical and clinical studies and its research and development programs, including establishing in vivo preclinical proof-of-concept for an undisclosed indication by year-end 2024, the timing for the Company's receipt and presentation of data from its clinical trials and preclinical studies, including presenting additional clinical data from the RUBY and EdiTHAL trials by year-end 2024, the potential of, and expectations for, the Company's product candidates, the timing or likelihood of regulatory filings and approvals, the Company's expectations regarding commercial readiness, and the Company's expectations regarding cash runway. The Company may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including: uncertainties inherent in the initiation and completion of pre-clinical studies and clinical trials, including the RUBY and EdiTHAL trials, and clinical development of the Company's product candidates, including reni-cel; availability and timing of results from pre-clinical studies and clinical trials; whether interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; expectations for regulatory approvals to conduct trials or to market products and availability of funding sufficient for the Company's foreseeable and unforeseeable operating expenses and capital expenditure requirements. These and other risks are described in greater detail under the caption "Risk Factors" included in the Company's most recent Annual Report on Form 10-K, which is on file with the Securities and Exchange Commission, as updated by the Company's subsequent filings with the Securities and Exchange Commission, and in other filings that the Company may make with the Securities and Exchange Commission in the future. Any forward-looking statements contained in this press release represent the Company's views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Except as required by law, the Company explicitly disclaims any obligation to update any forward-looking statements.

    This press release contains hyperlinks to information that is not deemed to be incorporated by reference in this press release.



    EDITAS MEDICINE, INC.

    Consolidated Statement of Operations

    (amounts in thousands, except share and per share data)

    (Unaudited)

     
     Three Months Ended

    June 30,
     Six Months Ended

    June 30,
      2024   2023   2024   2023 
    Collaboration and other research and development revenues$513  $2,887  $1,649  $12,738 
    Operating expenses:       
    Research and development 54,210   29,779   102,997   67,583 
    General and administrative 18,206   17,202   37,545   40,211 
    Total operating expenses 72,416   46,981   140,542   107,794 
    Operating loss (71,903)  (44,094)  (138,893)  (95,056)
    Other income, net:       
    Other income (expense), net (1)  (7)  5   (1,590)
    Interest income, net 4,297   3,811   9,331   7,320 
    Total other income, net 4,296   3,804   9,336   5,730 
    Net loss$(67,607) $(40,290) $(129,557) $(89,326)
    Net loss per share, basic and diluted (0.82)  (0.56)  (1.58)  (1.27)
    Weighted-average common shares outstanding, basic and diluted 82,310,368   71,376,678   82,124,603   70,157,204 



    EDITAS MEDICINE, INC.

    Selected Consolidated Balance Sheet Items

    (amounts in thousands)

    (Unaudited)

        
     June 30, December 31,
     2024 2023
    Cash, cash equivalents, and marketable securities$318,307 $427,135
    Working capital 212,048  277,612
    Total assets 384,801  499,153
    Deferred revenue, net of current portion 54,204  60,667
    Total stockholders' equity 232,009  349,097


    Media and Investor Contact:
    Cristi Barnett
    (617) 401-0113
    [email protected]

    Primary Logo

    Get the next $EDIT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EDIT

    DatePrice TargetRatingAnalyst
    4/28/2025$3.00Buy
    H.C. Wainwright
    12/16/2024Neutral → Underweight
    Analyst
    12/13/2024Buy → Neutral
    Chardan Capital Markets
    12/13/2024Buy → Hold
    Truist
    12/13/2024$11.00 → $3.00Buy → Hold
    Stifel
    12/11/2024$7.00 → $4.00Overweight → Equal Weight
    Wells Fargo
    11/25/2024$13.00 → $1.00Buy → Underperform
    BofA Securities
    11/6/2024In-line → Outperform
    Evercore ISI
    More analyst ratings

    $EDIT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by SVP, Chief Financial Officer Parison Amy

      4 - Editas Medicine, Inc. (0001650664) (Issuer)

      4/8/25 4:29:42 PM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • New insider Parison Amy claimed ownership of 17,952 shares (SEC Form 3)

      3 - Editas Medicine, Inc. (0001650664) (Issuer)

      4/8/25 4:20:50 PM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by EVP, CHIEF FINANCIAL OFFICER Lucera Erick

      4 - Editas Medicine, Inc. (0001650664) (Issuer)

      3/27/25 4:41:59 PM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $EDIT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Editas Medicine to Announce First Quarter 2025 Financial Results and to Participate in Investor Conference in May

      CAMBRIDGE, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that it plans to announce Q1 2025 financial results and business updates on May 12 via press release and SEC filings. As previously announced, the Company does not plan to host quarterly financial results conference calls moving forward. Additionally, Editas Medicine management will participate in the following upcoming investor conference in May: Bank of America Global Healthcare Conference Format: Fireside ChatDate: Tuesday, May 13Time: 5:15 p.m. PTLocation: Las Vegas, NV To access

      5/5/25 4:01:00 PM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Editas Medicine to Present Preclinical Data Demonstrating Progress in the Development of an in vivo Gene Editing Pipeline at the American Society of Gene and Cell Therapy Annual Meeting

      CAMBRIDGE, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a pioneering gene editing company, today announced that five abstracts have been accepted for presentation, including one oral presentation, at the 28th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) being held May 13 – 17, 2025, in New Orleans, LA, and virtually. The Company is presenting preclinical data to support its development of transformative in vivo gene editing medicines. Editas Medicine presentations at ASGCT include: Oral presentation of in vivo preclinical data from humanized mouse and non-human primate (NHP) studies using targeted lipid nanoparticles (tLNPs) to

      4/28/25 4:31:00 PM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Editas Medicine Announces Chief Financial Officer Transition

      Erick J. Lucera to Step Down as CFO to pursue another opportunity Senior Vice President of Finance Amy Parison Appointed CFO CAMBRIDGE, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a pioneering gene editing company, today announced Chief Financial Officer Erick J. Lucera is stepping down to pursue an external opportunity, effective March 28, 2025. Current Senior Vice President of Finance Amy Parison will succeed Mr. Lucera as Chief Financial Officer. "We are thrilled to promote Amy to the executive leadership team as our new CFO. Amy joined Editas two and a half years ago as our head of Finance, working closely with the CFO. Her track record of financia

      3/20/25 4:01:00 PM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $EDIT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Hopfield Jessica bought $253,868 worth of shares (45,000 units at $5.64), increasing direct ownership by 198% to 67,700 units (SEC Form 4)

      4 - Editas Medicine, Inc. (0001650664) (Issuer)

      5/14/24 4:17:23 PM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $EDIT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Editas Medicine Inc.

      SC 13G/A - Editas Medicine, Inc. (0001650664) (Subject)

      11/12/24 2:30:25 PM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Editas Medicine Inc.

      SC 13G/A - Editas Medicine, Inc. (0001650664) (Subject)

      11/4/24 11:57:08 AM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Editas Medicine Inc.

      SC 13G/A - Editas Medicine, Inc. (0001650664) (Subject)

      10/17/24 1:10:31 PM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $EDIT
    Financials

    Live finance-specific insights

    See more
    • Editas Medicine Announces Fourth Quarter and Full Year 2024 Results and Business Updates

      On track to declare two in vivo editing development candidates via gene upregulation, one in HSCs and one in liver, in mid-2025Company to present further in vivo HSC preclinical data and further in vivo preclinical data in one liver indication by year-endOn track to establish one additional target cell type/tissue by year-endStrong cash position with operational runway into the second quarter of 2027 CAMBRIDGE, Mass., March 05, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today reported financial results for the fourth quarter and full year 2024 and provided business upd

      3/5/25 4:05:00 PM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Editas Medicine Announces Strategic Transition to in vivo Gene Editing Company with Intent to Achieve Human Proof of Concept in Approximately Two Years

      Focus on in vivo CRISPR-edited medicines based on Editas researchers' recent scientific progress in multiple tissues: Achieved pre-clinical in vivo proof of concept of high level HBG1/2 promoter editing and HbF induction in a humanized mouse model for treatment of sickle cell disease and beta thalassemia with a single dose of an HSC-targeted lipid nanoparticle (tLNP) formulationAchieved in vivo proof of concept of high efficiency editing in the liver in non-human primates Ending development of reni-cel after extensive search did not yield a commercial partner The Company will work closely with the clinical trial sites, regulators, and other parties to determine the path forward for patien

      12/12/24 4:00:00 PM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Editas Medicine Announces Third Quarter 2024 Results and Business Updates

      Achieved in vivo preclinical proof of concept of HBG1/2 editing in hematopoietic stem and progenitor cells (HSPCs) using Editas Medicine's proprietary targeted LNP in a key step to developing a novel in vivo treatment for sickle cell disease and beta thalassemia On track to share additional clinical and patient reported outcomes data from 28 patients in the RUBY trial for sickle cell disease at the American Society of Hematology (ASH) Annual Meeting and Exposition in December Company to provide an update on its in vivo progress and pipeline development in 1Q 2025 Company expects the existing cash, cash equivalents, and marketable securities, together with the upfront cash payment from DRI

      11/4/24 7:30:00 AM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $EDIT
    SEC Filings

    See more
    • SEC Form DEFA14A filed by Editas Medicine Inc.

      DEFA14A - Editas Medicine, Inc. (0001650664) (Filer)

      4/15/25 4:17:58 PM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEF 14A filed by Editas Medicine Inc.

      DEF 14A - Editas Medicine, Inc. (0001650664) (Filer)

      4/15/25 4:16:31 PM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form PRE 14A filed by Editas Medicine Inc.

      PRE 14A - Editas Medicine, Inc. (0001650664) (Filer)

      4/4/25 4:38:47 PM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $EDIT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright initiated coverage on Editas Medicine with a new price target

      H.C. Wainwright initiated coverage of Editas Medicine with a rating of Buy and set a new price target of $3.00

      4/28/25 8:37:22 AM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Editas Medicine downgraded by Analyst

      Analyst downgraded Editas Medicine from Neutral to Underweight

      12/16/24 6:44:11 AM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Editas Medicine downgraded by Chardan Capital Markets

      Chardan Capital Markets downgraded Editas Medicine from Buy to Neutral

      12/13/24 8:14:41 AM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $EDIT
    Leadership Updates

    Live Leadership Updates

    See more
    • Editas Medicine Strengthens Executive Leadership Team with Appointment of Caren Deardorf as Chief Commercial and Strategy Officer

      CAMBRIDGE, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a clinical-stage genome editing company, today announced the appointment of Caren Deardorf as the Company's first Chief Commercial and Strategy Officer. Ms. Deardorf will build and lead Editas Medicine's commercial organization, strategy, and execution to support all launch, commercialization, and lifecycle management activities of the Company's current and future pipeline of products. "As we drive our lead program EDIT-301 towards commercialization, I am happy to welcome a commercial leader of Caren's caliber to Editas. Caren has a proven ability to translate early discovery and clinical assets into

      9/25/23 9:00:00 AM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Medicenna Announces the Appointment of Jeff Caravella as Chief Financial Officer

      Jeff Caravella brings over two decades of healthcare expertise steering strategic, financial and operational functions at leading public life-science corporations Mr. Caravella's appointment demonstrates Medicenna's continuing commitment to establish its presence in Boston, the leading biotechnology ecosystem TORONTO and HOUSTON, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (NASDAQ:MDNA, TSX:MDNA), a clinical-stage immunotherapy company, today announced the appointment of Jeff Caravella as Chief Financial Officer (CFO). In this position, Mr. Caravella will lead Medicenna's financial strategy to support the Company's growth. This appointmen

      8/28/23 7:00:57 AM ET
      $EDIT
      $MDNA
      $TNGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Editas Medicine Strengthens Executive Leadership Team with Appointment of Linda C. Burkly, Ph.D., as Chief Scientific Officer

      CAMBRIDGE, Mass., July 24, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a clinical-stage genome editing company, today announced the appointment of Linda C. Burkly, Ph.D., as the Company's Executive Vice President and Chief Scientific Officer. Dr. Burkly will lead Editas' drug discovery team and activities related to Editas Medicine's pipeline of experimental medicines across all therapeutic areas and indications. "Earlier this year, we shared our vision to be a leader in programable in vivo gene editing, and I couldn't be happier that Linda is joining Editas to help make this vision a reality. Linda has an outstanding track record of inventing or contributing to the fo

      7/24/23 7:00:00 AM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care